Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2145386, 14 pages
https://doi.org/10.1155/2017/2145386
Research Article

Immune Response and Protective Efficacy of a Heterologous DNA-Protein Immunization with Leishmania Superoxide Dismutase B1

1Department of Biological Sciences, University of Calgary, Room 374, 2500 University Drive NW, Calgary, AB, Canada T2N 1N4
2Department of Medical Parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia
3The Forsyth Institute, Cambridge, MA 02142, USA

Correspondence should be addressed to Abebe Genetu Bayih; moc.liamg@utenegebeba

Received 26 May 2017; Accepted 19 October 2017; Published 22 November 2017

Academic Editor: Carmen Thomas

Copyright © 2017 Abebe Genetu Bayih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Desjeux, “Leishmaniasis: current situation and new perspectives,” Comparative Immunology, Microbiology & Infectious Diseases, vol. 27, no. 5, pp. 305–318, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. WHO, WHO, Third WHO Report on Neglected Tropical Diseases, 2015.
  3. S. L. Croft, S. Sundar, and A. H. Fairlamb, “Drug resistance in leishmaniasis,” Clinical Microbiology Reviews, vol. 19, no. 1, pp. 111–126, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Sundar and J. Chakravarty, “Leishmaniasis: an update of current pharmacotherapy,” Expert Opinion on Pharmacotherapy, vol. 14, no. 1, pp. 53–63, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Khamesipour, S. Rafati, N. Davoudi, F. Maboudi, and F. Modabber, “Leishmaniasis vaccine candidates for development: a global overview,” Indian Journal of Medical Research, vol. 123, no. 3, pp. 423–438, 2006. View at Google Scholar · View at Scopus
  6. R. Kumar and C. Engwerda, “Vaccines to prevent leishmaniasis,” Clinical translational immunology, vol. 3, no. 3, p. e13, 2014. View at Publisher · View at Google Scholar
  7. I. Okwor, Z. Mou, D. Liu, and J. Uzonna, “Protective immunity and vaccination against cutaneous leishmaniasis,” Frontiers in Immunology, vol. 3, no. MAY, Article ID Article 128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Chakravarty, S. Kumar, S. Trivedi et al., “A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis,” Vaccine, vol. 29, no. 19, pp. 3531–3537, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Llanos-Cuentas, W. Calderón, M. Cruz et al., “A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis,” Vaccine, vol. 28, no. 46, pp. 7427–7435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Nascimento, D. F. Fernandes, E. P. Vieira et al., “A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis,” Vaccine, vol. 28, no. 40, pp. 6581–6587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. G. Bayih, N. S. Daifalla, and L. Gedamu, “DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant,” PLOS Neglected Tropical Diseases, vol. 8, no. 12, article e3391, 2014. View at Publisher · View at Google Scholar
  12. N. S. Daifalla, A. G. Bayih, and L. Gedamu, “Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection,” Experimental Parasitology emphasizes, vol. 131, no. 3, pp. 317–324, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. T. LoVerde, C. Carvalho-Queiroz, and R. Cook, “Vaccination with antioxidant enzymes confers protective immunity against challenge infection with Schistosoma mansoni,” Memórias do Instituto Oswaldo Cruz, vol. 99, 1, no. 5, pp. 37–43, 2004. View at Google Scholar · View at Scopus
  14. H. Singha, A. I. Mallick, C. Jana et al., “Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus,” Microbes and Infection, vol. 10, no. 10-11, pp. 1089–1096, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. W. J. Paramchuk, S. O. Ismail, A. Bhatia, and L. Gedamu, “Cloning, characterization and overexpression of two iron superoxide dismutase cDNAs from Leishmania chagasi: Role in pathogenesis,” Molecular and Biochemical Parasitology, vol. 90, no. 1, pp. 203–221, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. K. A. Plewes, S. D. Barr, and L. Gedamu, “Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival,” Infection and Immunity, vol. 71, no. 10, pp. 5910–5920, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Genetu, E. Gadisa, A. Aseffa et al., “Leishmania aethiopica: Strain identification and characterization of superoxide dismutase-B genes,” Experimental Parasitology emphasizes, vol. 113, no. 4, pp. 221–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. N. S. Daifalla, A. G. Bayih, and L. Gedamu, “Immunogenicity of Leishmania donovani iron superoxide dismutase B1 and peroxidoxin 4 in BALB/c mice: the contribution of Toll-like receptor agonists as adjuvant,” Experimental Parasitology emphasizes, vol. 129, no. 3, pp. 292–298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. B. L. S. Campos, T. N. Silva, S. P. Ribeiro et al., “Analysis of iron superoxide dismutase-encoding DNA vaccine on the evolution of the Leishmania amazonensis experimental infection,” Parasite Immunology, vol. 37, no. 8, pp. 407–416, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. P. A. Darrah, D. T. Patel, P. M. De Luca et al., “Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major,” Nature Medicine, vol. 13, no. 7, pp. 843–850, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. N. S. Daifalla, A. G. Bayih, and L. Gedamu, “Differential Immune Response against Recombinant Leishmania donovani Peroxidoxin 1 and Peroxidoxin 2 Proteins in BALB/c Mice,” Journal of Immunology Research, vol. 2015, Article ID 348401, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Yeganeh, F. Barkhordari, M. Omidi et al., “Cloning and expression of leishmania major superoxide dismutase b1: a potential target antigen for serodiagnosis of leishmaniasis,” Iranian Journal of Immunology, vol. 6, no. 3, pp. 130–140, 2009. View at Google Scholar · View at Scopus
  23. K. Kaushansky, J. A. Lopez, and C. B. Brown, “Role of carbohydrate modification in the production and secretion of human granulocyte macrophage colony-stimulating factor in genetically engineered and normal mesenchymal cells,” Biochemistry, vol. 31, no. 6, pp. 1881–1886, 1992. View at Publisher · View at Google Scholar · View at Scopus
  24. M. L. Disis, H. Bernhard, F. M. Shiota et al., “Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines,” Blood, vol. 88, no. 1, pp. 202–210, 1996. View at Google Scholar · View at Scopus
  25. W. R. Weiss, K. J. Ishii, R. C. Hedstrom et al., “A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine,” The Journal of Immunology, vol. 161, no. 5, pp. 2325–2332, 1998. View at Google Scholar · View at Scopus
  26. E. A. James, C. Wang, Z. Wang et al., “Production and characterization of biologically active human GM-CSF secreted by genetically modified plant cells,” Protein Expression and Purification, vol. 19, no. 1, pp. 131–138, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Tenbusch, S. Kuate, B. Tippler et al., “Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity,” BMC Immunology, vol. 9, article no. 13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y. A. W. Skeiky, and S. G. Reed, “Vaccination with plasmid DNA encoding TSA/LmSTI1 Leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice,” Infection and Immunity, vol. 70, no. 6, pp. 2828–2836, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Gurunathan, D. L. Sacks, D. R. Brown et al., “Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major,” The Journal of Experimental Medicine, vol. 186, no. 7, pp. 1137–1147, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Laddy and D. Weiner, “From plasmids to protection: A review of DNA vaccines against infectious diseases,” International Reviews of Immunology, vol. 25, no. 3-4, pp. 99–123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Liu, “DNA vaccines: an historical perspective and view to the future,” Immunological Reviews, vol. 239, no. 1, pp. 62–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Mazumder, M. Maji, A. Das, and N. Ali, “Potency, efficacy and durability of DNA/DNA, DNA/ protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice,” PLoS ONE, vol. 6, no. 2, Article ID e14644, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Y. Liew, Y. Li, and S. Millott, “Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmama major through the induction of nitric oxide,” The Journal of Immunology, vol. 145, no. 12, pp. 4306–4310, 1990. View at Google Scholar · View at Scopus
  34. D. Sacks and N. Noben-Trauth, “The immunology of susceptibility and resistance to Leishmania major in mice,” Nature Reviews Immunology, vol. 2, no. 11, pp. 845–858, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. C. C. Stempin, L. R. Dulgerian, V. V. Garrido, and F. M. Cerban, “Arginase in parasitic infections: macrophage activation, immunosuppression, and intracellular signals,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 683485, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. T. L. Stevens, A. Bossie, V. M. Sanders et al., “Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells,” Nature, vol. 334, no. 6179, pp. 255–258, 1988. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Rostamian, S. Sohrabi, H. Kavosifard, and H. M. Niknam, “Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB/c mice,” Journal of Microbiology, Immunology and Infection, vol. 50, no. 2, pp. 160–166, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. J. E. Uzonna, G. Wei, D. Yurkowski, and P. Bretscher, “Immune elimination of Leishmania major in mice: Implications for immune memory, vaccination, and reactivation disease,” The Journal of Immunology, vol. 167, no. 12, pp. 6967–6974, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. L. López-Fuertes, E. Pérez-Jiménez, A. J. Vila-Coro et al., “DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice,” Vaccine, vol. 21, no. 3-4, pp. 247–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Rafati, A.-H. Salmanian, T. Taheri, M. Vafa, and N. Fasel, “A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major,” Vaccine, vol. 19, no. 25-26, pp. 3369–3375, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. C. B. Stober, U. G. Lange, M. T. M. Roberts, A. Alcami, and J. M. Blackwell, “IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection,” The Journal of Immunology, vol. 175, no. 4, pp. 2517–2524, 2005. View at Publisher · View at Google Scholar · View at Scopus